According to a meta-analysis performed by researchers at the Tisch Cancer Institute at Mount Sinai Medical Center, older, cisplatin-based combination chemotherapy regimens are better in the treatment of a type of bladder cancer, advanced urothelial carcinoma, than carboplatin-based regimens.
Researchers examined all the available papers in PubMed dating between 1966 and 2010 and found four randomized trials involving 286 patients total.
Although cisplatin-based regimens are considered standard treatment for advanced urothelial carcinoma, carboplatin-based regimens are often chosen because of the increased tolerability of carboplatin over cisplatin.
However, this meta-analysis is clear that cisplain-based regimens are associated with a significantly higher likelihood of complete response and overall response in this specific patient population.
Source: Annals of Oncology
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
